Wolverine Asset Management LLC Clovis Oncology, Inc. Put Options Transaction History

Wolverine Asset Management LLC

$4.35 Billion
Q3 2024

Put Options

16 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 04, 2022	SELL	$1.43 - $3.14 $8,008 - $17,584	-5,600 Reduced 5.3%	100,100 $202,000
Q4 2021 Feb 09, 2022	BUY	$2.7 - $4.76 $270 - $476	100 Added 0.09%	105,700 $286,000
Q3 2021 Nov 12, 2021	BUY	$4.06 - $5.8 $405,999 - $580,000	100,000 Added 1785.71%	105,600 $470,000
Q2 2021 Aug 13, 2021	SELL	$5.02 - $7.05 $5,020 - $7,050	-1,000 Reduced 15.15%	5,600 $32,000
Q1 2021 May 13, 2021	SELL	$4.81 - $10.34 $2.34 Million - $5.03 Million	-486,600 Reduced 98.66%	6,600 $46,000
Q4 2020 Feb 12, 2021	BUY	$4.13 - $6.41 $25,193 - $39,101	6,100 Added 1.25%	493,200 $2.37 Million
Q2 2020 Aug 13, 2020	SELL	$5.69 - $9.69 $718,078 - $1.22 Million	-126,200 Reduced 20.58%	487,100 $3.29 Million
Q1 2020 May 13, 2020	SELL	$3.77 - $11.0 $249,951 - $729,300	-66,300 Reduced 9.76%	613,300 $3.9 Million
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $789,900 - $4.33 Million	263,300 Added 63.25%	679,600 $7.08 Million
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $1.54 Million - $6.02 Million	392,300 Added 1634.58%	416,300 $1.64 Million
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $125,538 - $251,566	9,800 Added 69.01%	24,000 $356,000
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $28,256 - $48,448	-1,600 Reduced 10.13%	14,200 $352,000
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $88,388 - $248,292	7,600 Added 92.68%	15,800 $283,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $766,836 - $1.04 Million	-15,300 Reduced 65.11%	8,200 $432,000
Q3 2017 Nov 14, 2017	SELL	$67.17 - $84.81 $853,059 - $1.08 Million	-12,700 Reduced 35.08%	23,500 $1.94 Million
Q2 2017 Aug 14, 2017	BUY	N/A	36,200	36,200 $3.39 Million

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Asset Management LLC with notifications on news.

Account